New migraine treatments have brought stunning relief to many people by blocking the action of calcitonin gene-related peptide (CGRP), a protein in the brain involved in the migraine process.

If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist ...

Existing treatments for endometriosis have changed little in the past 30 years and are often ineffective or have undesired ...

Atogepant, a new oral prescription drug, shows promise in preventing migraines by targeting CGRP receptors, reducing migraine ...

Discover the latest breakthroughs in migraine treatment for 2025, including CGRP inhibitors, AI-powered personalized plans, wearable neuroregulators, and mRNA-based therapies. Learn expert ...

Compared with the use of other migraine medications, use of erenumab did not increase cardiovascular or cerebrovascular risks.

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Zavegepant was effective in relieving acute migraine symptoms, with a safety profile similar to other oral calcitonin gene-related peptide receptor antagonists.

Atogepant, taken orally once daily, belongs to a class of drugs called calcitonin gene-related peptide (CGRP) receptor antagonists. CGRP is a protein that plays a key role in migraine development ...

Pfizer’s Vydura has become the first oral CGRP antagonist recommended for routine use by the NHS to prevent episodic migraine attacks, after being rejected earlier this year as an acute treatment.

Merck has announced that the antagonist of the calcitonin gene-related peptide (CGRP) receptor telcagepant has met the primary end points in two Phase III trials to treat migraine, which is ...

If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in ...